HC Wainwright Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report report published on Wednesday, TipRanks reports. HC Wainwright currently has a $4.00 price objective on the stock.

Several other brokerages have also issued reports on LCTX. Zacks Investment Research lowered Lineage Cell Therapeutics from a hold rating to a sell rating in a research report on Thursday, October 10th. ValuEngine raised Lineage Cell Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, October 16th. Chardan Capital reaffirmed a buy rating on shares of Lineage Cell Therapeutics in a research report on Thursday, August 22nd. Finally, Maxim Group set a $3.00 target price on Lineage Cell Therapeutics and gave the stock a buy rating in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Lineage Cell Therapeutics presently has a consensus rating of Buy and an average target price of $2.67.

NYSEAMERICAN:LCTX traded up $0.07 during trading hours on Wednesday, hitting $0.87. 747,921 shares of the company were exchanged, compared to its average volume of 613,741. Lineage Cell Therapeutics has a one year low of $0.66 and a one year high of $1.87. The business’s fifty day moving average is $0.98.

Hedge funds have recently bought and sold shares of the company. Defender Capital LLC. bought a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $3,709,000. Moors & Cabot Inc. bought a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $34,000. Creative Planning bought a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $201,000. Commonwealth Equity Services LLC bought a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $112,000. Finally, Rhumbline Advisers bought a new stake in Lineage Cell Therapeutics in the 3rd quarter valued at about $177,000.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

See Also: Swap

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.